Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Investor Presentation (June 2024)
49 slides from Puma Biotechnology's investor presentation, June 2024
Slide 1: Puma Biotechnology
Puma Biotechnology June 2024
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: Product Pipeline
Product Pipeline Phase I Phase II Phase III Registration Approval N Neratinib: Tyrosine kinase inhibitor HER2+ Breast Cancer ExteNET (Phase III HER2+ EBC*) Extended adjuvant Neratinib monotherapy CONTROL Metastatic Monotherapy or combo therapy NALA (Phase III 3rd Line HER2+ MBC**) Metastatic w/ brai
Slide 4: Puma's Pharmacy and Distributor Network
Puma’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina
Slide 5: $40.3 Million Net NERLYNX Revenue in Q1'24
$40.3 Million Net NERLYNX Revenue in Q1’24 ~14% decline in Q1’24 compared to Q1’23 ~24% decrease Q1’24 compared to Q4’23 Net Revenue (in $MM) Net Revenue (in $MM) 46.8 53.2 40.3 40.3 Q1'2023 Q1'2024 Q4'2023 Q1'2024 Inventory Change ($) Inventory Change ($) Q1’2023 Q1’2024 Q4’2023 Q1’2024 -$3.8 mil -
Slide 6: 2,410 Ex-Factory Bottles Were Sold in Q1'24
2,410 Ex-Factory Bottles Were Sold in Q1’24 ~15% decline in Q1’24 compared to Q1’23 ~16% decline in Q1’24 compared to Q4’23 Bottles Bottles 2,849 2,410 2,881 2,410 Q1'2023 Q1'2024 Q4'2023 Q1'2024 Inventory Change Bottles Inventory Change Bottles Q1’2023 Q1’2024 Q4’2023 Q1’2024 -236 -120 +127 -120 Co
Slide 7: ~67% of Patients in Q1'24 Started at a Reduced Dose
~67% of Patients in Q1’24 Started at a Reduced Dose* % of Patients Starting at Reduced Dose 76.4% 67.9% 69.5% 71.2% 65.4% 66.7% 64.0% 64.0% 61.5% 59.4% 54.9% 42.4% 37.7% 38.7% 32.8% 30.0% 31.0% 28.0% 19.0% 12.0% 11.0% 6.0% 7.0% 4.0% 2.0% 2.0% 3.0% *Reduced dose defined as fewer than 6 pills per day
Slide 8: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • 2020 – Singapore Australia / SE Asia • 2022 – Ext. Adj. in the Philippines; mBC in Singapore • 2021 – Malays
Slide 9: NERLYNX Extended Adjuvant HER2+ Breast Cancer Market Size
NERLYNX® Extended Adjuvant HER2+ Breast Cancer Market Size Approximately 28,300 patients (US) with early stage HER2+ breast cancer treated with adjuvant treatment1 Approximately 6,000 patients (US) with HR positive early stage HER2+ breast cancer and no pathological complete response to neoadjuvant
Slide 10: Puma Financial Guidance for Q2 and FY 2024
Puma Financial Guidance for Q2 and FY 2024 Q2 2024 Full Year 2024 NERLYNX revenue guidance: $43 – $45 million $183 - 190 million NERLYNX royalty guidance: $2.5 - 3 million $30 - 34 million NERLYNX license revenue: $0 million $1 – 2 million Net income (loss): $(6) - (9) million $12 - 15 million Gross
Slide 11: ALISERTIB
ALISERTIB Breast Cancer and Small-Cell Lung Cancer
Slide 12: Alisertib (MLN 8237) Aurora Kinase A inhibitor
Alisertib (MLN 8237) Orally Bioavailable Aurora Kinase A Drug Class: Benzazepine (AURKA) inhibitor • Single-agent and combinational clinical activity in solid tumors including hormone receptor-positive breast cancer (HR+ MBC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), and
Slide 13: Synthetic Lethality of AURKA and Rb1
Synthetic Lethality of AURKA and Rb1 Cancers with a hypersensitive spindle assembly checkpoint (SAC) depend on AURKA for mitotic exit and survival1 • Loss of function of Rb1 is a common event in cancer and can emerge as a mechanism of resistance to EGFR, CDK4, and ER-targeted therapies in breast and
Slide 14: AURKA and c-Myc Co-regulate Each Other
AURKA and c-Myc Co-regulate Each Other Nuclear AURKA exerts kinase-independent functions by acting as a transcription factor AURKA c-Myc Genomic instability & • AURKA and c-Myc transcriptionally upregulate each other, tumor development suggesting the existence of a positive feedback loop E2F1 cyclin
Slide 15: Clinical Development in Small-Cell Lung Cancer
Clinical Development in Small-Cell Lung Cancer
Slide 16: Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts Study design: • Pts had to have undergone ≤ 2 previous cytotoxic regimens, not including adjuvant or neoadjuvant treatments • Alisertib administration: orally in 21-day cycles at 50 mg twice daily for 7 days followed by a break of
Slide 17: Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts 10 (21%; 95% CI 10–35) of 48 patients had an objective response; all responders achieved a partial response Change in target lesion size and best response (investigator assessed response) PD=progressive disease. SD=stable disease.
Slide 18: Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - SCLC Cohorts All-cause adverse events in safety evaluable SCLC cohort (n=60) Table adapted from Melichar B Lancet Oncol 2015. Data are number of patients with AE (%) for AEs of any grade in at least 10% of patients overall. NA = not applicable
Slide 19: Randomized Phase 2 Study of Paclitaxel plus Alisertib: Primary Analysis
Randomized Phase 2 Study of Paclitaxel plus Alisertib vs Paclitaxel plus Placebo as Second-Line SCLC: Primary Analysis Study design: • Patients with relapsed or refractory SCLC stratified by relapse type (sensitive vs resistant or refractory) • Randomized 1:1 to alisertib + paclitaxel or placebo + p
Slide 20: Randomized Phase 2 Study: Correlative Biomarker Analysis
Randomized Phase 2 Study of Paclitaxel plus Alisertib vs Paclitaxel plus Placebo as Second-Line SCLC: Correlative Biomarker Analysis Improved PFS observed among patients positive versus negative for c-Myc expression PFS in patients positive for c-Myc expression Median PFS 4.64 mo w/ paclitaxel + ali
Slide 21: Randomized Phase 2 Study: Correlative Biomarker Analysis
Randomized Phase 2 Study of Paclitaxel plus Alisertib vs Paclitaxel plus Placebo as Second-Line SCLC: Correlative Biomarker Analysis Improved outcomes among pts with genetic alternations in cell cycle genes CDK6, RBL1, RBL2, and RB1 (collectively referred to as “mutant”) Owonikoko J Thorac Oncol 202
Slide 22: Randomized Phase 2 Study: Safety
Randomized Phase 2 Study of Paclitaxel plus Alisertib vs Paclitaxel plus Placebo as Second-Line SCLC: Safety AE, adverse event Owonikoko J Thorac Oncol 2020 22
Slide 23: PUMA-ALI-4201 Phase II study design
PUMA-ALI-4201 Phase II study design Key inclusion criteria • Pathologically confirmed ES-SCLC • Progression on or after first-line platinum- based chemo; must have prior immunotherapy Alisertib • Measurable disease per RECIST v1.1 N = up to 60 50 mg po BID on days 1-7 of every 21-day • Must provide
Slide 24: Efficacy and safety objectives and endpoints
Efficacy and safety objectives and endpoints Objective Primary Endpoint • Proportion of patients with confirmed complete responses (CR) or partial responses (PR) as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) Secondary Endpoints • Duration of response (DOR) • Di
Slide 25: Parallel Clinical and Biomarker Development
Parallel Clinical and Biomarker Development Comprehensive biomarker strategy supports clinical development and commercialization Drug Enrollment of ALI-4201 Data Amended ALI-4201 for biomarker Treatment development (up to 60 pts) Analysis defined population to support potential Accelerated Approval
Slide 26: Clinical Development in Non-Small Cell Lung Cancer
Clinical Development in Non-Small Cell Lung Cancer
Slide 27: A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC
A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC 27
Slide 28: A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC
A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC ASCO Annual Meeting 2024
Slide 29: A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC
A Phase I Investigator-Initiated Trial of Osimertinib + Alisertib in EGFR-Mutated NSCLC ASCO Annual Meeting 2024 29
Slide 30: Clinical Development of Alisertib in Breast Cancer
Clinical Development of Alisertib in Breast Cancer
Slide 31: Phase 2 Study of Alisertib Monotherapy - Breast Cancer Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - Breast Cancer Cohorts Study design: • Pts had to have undergone ≤ 2 previous cytotoxic regimens, not including adjuvant or neoadjuvant treatments • Alisertib administered orally in 21-day cycles at 50 mg twice daily for 7 days followed by a br
Slide 32: Phase 2 Study of Alisertib Monotherapy - Breast Cancer Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - Breast Cancer Cohorts 9 / 49 patients (18%; 95% CI 9–32) had an objective response; all responders achieved a partial response Change in target lesion size and best response (investigator assessed response) PD=progressive disease. SD=stable di
Slide 33: Phase 2 Study of Alisertib Monotherapy - Breast Cancer Cohorts
Phase 2 Study of Alisertib Monotherapy in Solid Tumors - Breast Cancer Cohorts All-cause adverse events in safety evaluable breast cancer cohort (n=53) Table adapted from Melichar B Lancet Oncol 2015. Data are number of patients with AE (%) for AEs of any grade in at least 10% of patients overall. N
Slide 34: Phase 2 Randomized Trial of Alisertib + Fulvestrant vs Alisertib in HR+ Breast Cancer
Phase 2 Randomized Trial of Alisertib + Fulvestrant vs Alisertib in Advanced HR+ Breast Cancer Patients (n=96) Regimen & Schedule Patients Inclusion (n=96) Criteria • Alisertib + Fulvestrant: Alisertib 50 mg PO • Post-menopausal women BID on days 1-3, 8-10, 15-17 q 28-day cycle • Histologically-prov
Slide 35: Phase 2 Randomized Trial of Alisertib + Fulvestrant vs Alisertib in HR+ Breast Cancer
Phase 2 Randomized Trial of Alisertib + Fulvestrant vs Alisertib in Advanced HR+ Breast Cancer Haddad TC SABCS 2020 PD2-05 35
Slide 36: Phase 2 Randomized Study of Paclitaxel + Alisertib vs Paclitaxel Alone
Phase 2 Randomized Study of Paclitaxel + Alisertib vs Paclitaxel Alone - Efficacy in ER+/HER2- MBC Cohort PFS in ER+/HER2- ITT Study design: Median PFS: 10.2 (3.8-15.7) mo for • Patients with ER+/HER2- or triple negative metastatic paclitaxel + alisertib vs 7.1 (3.8-10.6) breast cancer stratified by
Slide 37: Efficacy in ER+/HER2- MBC Cohort Pretreated with Palbociclib
Phase 2 Randomized Study of Paclitaxel + Alisertib vs Paclitaxel Alone - Efficacy in ER+/HER2- MBC Cohort Pretreated with Palbociclib Efficacy in patients pretreated with palbociclib (n=30) • Median PFS: 13.9 (5.6-15.6) mo (14 pts) w/ paclitaxel + alisertib vs 5.6 (3.0-10.6) mo (16 pts) w/ paclitaxe
Slide 38: Rb1 Loss and c-Myc Upregulation Correlate with Palbociclib Resistance
Rb1 Loss and c-Myc Upregulation Correlate with Palbociclib Resistance Both RB1 loss and MYC upregulation were observed in palbociclib-resistant HR+ breast cancer cell lines, supporting a role for alisertib in this setting RB1 Loss C-Myc Upregulation Pandey Cancers 2020 38
Slide 39: Study-related Neutropenia in Metastatic Breast Cancer
Study-related Neutropenia in Metastatic Breast Cancer - Alisertib compared to other agents Regimen All-grade Neutropenia (%) Grade 3/4 Neutropenia (%) Febrile Neutropenia (%) Alisertib monotherapy 50 mg BID1 63%1 57%1 4%1 Alisertib monotherapy 50 mg BID2 Not reported2 42%2 Not reported2 Alisertib 50
Slide 40: PUMA-ALI-1201 Phase II dose optimization
PUMA-ALI-1201 Phase 2 dose optimization, biomarker evaluation in HR+/HER- MBC Key inclusion criteria: Arm 1 Alisertib 50 mg BID on Days 1-3, 8-10, • HR+/HER2- mBC patients who have Stratification 15-17 of a 28-day cycle + Endocrine 1:1:1 RANDOMIZATION factors received at least 2 prior lines of endoc
Slide 41: Intellectual Property for NERLYNX (neratinib)
Intellectual Property for NERLYNX (neratinib) Composition of matter patent issued (expires 2030) – Extended by USPTO in November 2021 per Hatch/Waxman Use in the treatment of cancer issued (expires 2025) Two polymorph patents issued (both expire 2028) Combination with capecitabine (expires 2031) Use
Slide 42: Intellectual Property for alisertib
Intellectual Property for alisertib Composition of matter patent issued (expires 2029) Use in the treatment of proliferative disorders (expires 2032) Use in the treatment of small cell lung cancer (expires 2033) Use in the treatment of breast cancer (expires 2034) Additional patents being filed and
Slide 43: Intellectual Property on EGFR T790M Mutations
Intellectual Property on EGFR T790M Mutations Issued claims in Europe, Asia, Australia (expires 2026) – Possibility to extend up to 5 years Issued claims in United States (expires 2026) Patent claims upheld after European Opposition Hearing (February 2014) – Patent claims upheld after Appeal to Euro
Slide 44: Puma – Expected Milestones
Puma – Expected Milestones ✓ Present biomarker studies from the randomized trial of alisertib plus fulvestrant versus alisertib alone in hormone receptor-positive, HER2-negative breast cancer (Q2 2024) ✓ Update data from the clinical trial of alisertib in combination with osimertinib in patients wit
Slide 45: Experienced Management Team
Experienced Management Team Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder – Chief Executive Officer, President, Founder, Cougar Biotechnology Jeff Ludwig Chief Commercial Officer – Eli Lilly, Astellas, Amgen Maximo F. Nougues Chief Financial Officer – Getinge AB, Boston Scie
Slide 46: Board of Directors
Board of Directors Alan H. Auerbach Chairman, Chief Executive Officer, President, Founder, Puma Biotechnology, Inc. Alessandra Cesano, MD, PhD Chief Medical Officer, ESSA Pharmaceuticals; NanoString; Cleave Biosciences; Nodality; Amgen; Biogen; SmithKline Allison Dorval CFO, Verve Therapeutics; Form
Slide 47: Puma Biotechnology – Financial
Puma Biotechnology – Financial Currently trading on NASDAQ: PBYI Cash, cash equivalents and marketable securities at March 31, 2024: $107 million Net loss in Q1 2024: $4.8 million Cash earned in Q1 2024: $11.2 million Private placements: – March 2022: 3,584,228 shares issued to Alan Auerbach and Ath
Slide 48: Company Highlights
Company Highlights NERLYNX® – first HER2-directed drug approved by FDA for extended adjuvant treatment of early-stage HER2+ breast cancer in patients who have received prior trastuzumab NERLYNX® – first HER2-directed tyrosine kinase inhibitor approved in both early stage and metastatic HER2+ breast
Slide 49: Puma Biotechnology
Puma Biotechnology June 2024
Puma Biotechnology — Investor Presentation (June 2024) on 6ix